Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise against tough cancers in first chinese trial

NCT ID NCT05460273

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 119 participants will receive the drug every 3 weeks until their cancer worsens. The goal is to see how well it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

  • Research Site

    Beijing, 100039, China

  • Research Site

    Beijing, 100044, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130012, China

  • Research Site

    Changchun, 130021, China

  • Research Site

    Chengdu, 610000, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Dalian, 116023, China

  • Research Site

    Fuzhou, 350001, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510100, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Harbin, 150081, China

  • Research Site

    Jinan, 250030, China

  • Research Site

    Jinan, 250117, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanchang, 330009, China

  • Research Site

    Shenyang, 110042, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.